-
-
-
-
-
-
-
Truist Reiterates Buy Rating on Viridian Therapeutic (VRDN) Following Veligrotug's FDA approval
-
-
-
-
-
-
-
Viridian Therapeutics, Inc. (VRDN) Tops Q1 EPS by 99c
-
-
-
-
-
-
-
Viridian Therapeutic (VRDN) PT Lowered to $32 at Evercore ISI
-
-
-
-
-
-
-
Jefferies on Viridian Therapeutic (VRDN): bears to argue commercial oppy not clean, bulls see de-risk
-
-
-
-
-
-
-
Viridian Therapeutic (VRDN) PT Raised to $45 at Evercore ISI
-
-
-
-
-
-
-
TD Cowen on Biotechnology: '10+ Potential "Thome Run" Catalysts To Watch In 2026'
-
-
-
-
-
-
-
Viridian submits drug application to FDA for thyroid eye disease treatment
-
445,919 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

